West Pharmaceutical Services Revenue Recognized from Contract Liability increased by 126.5% to $23.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 26.2%, from $18.30M to $23.10M. This is a positive signal — higher values indicate stronger performance for this metric.
Consistent conversion of contract liabilities into revenue indicates healthy project execution and fulfillment of customer obligations.
Revenue recognized during the current period that was previously recorded as a contract liability (deferred revenue) at...
Common in industries with long-term contracts or subscription-based models.
anet_revenue_from_contract_liability| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.00M | $1.60M | $9.70M | $7.80M | $6.10M | $21.30M | $6.10M | $5.80M | $15.50M | $8.70M | $8.60M | $18.30M | $10.80M | $10.20M | $23.10M |
| QoQ Change | — | -85.5% | +506.3% | -19.6% | -21.8% | +249.2% | -71.4% | -4.9% | +167.2% | -43.9% | -1.1% | +112.8% | -41.0% | -5.6% | +126.5% |
| YoY Change | — | — | — | -29.1% | +281.3% | +119.6% | -21.8% | -4.9% | -27.2% | +42.6% | +48.3% | +18.1% | +24.1% | +18.6% | +26.2% |